These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 27749238)
1. Efficacy and safety of down-titration versus continuation strategies of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis with low disease activity or in remission: a systematic review and meta-analysis. Jiang M; Ren F; Zheng Y; Yan R; Huang W; Xia N; Luo L; Zhou J; Tang L Clin Exp Rheumatol; 2017; 35(1):152-160. PubMed ID: 27749238 [TBL] [Abstract][Full Text] [Related]
2. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908 [TBL] [Abstract][Full Text] [Related]
3. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448 [TBL] [Abstract][Full Text] [Related]
4. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438 [TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Choy EH; Smith C; Doré CJ; Scott DL Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080 [TBL] [Abstract][Full Text] [Related]
6. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Sesin CA; Bingham CO Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512 [TBL] [Abstract][Full Text] [Related]
8. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991 [TBL] [Abstract][Full Text] [Related]
9. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350 [TBL] [Abstract][Full Text] [Related]
10. Tocilizumab for rheumatoid arthritis. Singh JA; Beg S; Lopez-Olivo MA Cochrane Database Syst Rev; 2010 Jul; (7):CD008331. PubMed ID: 20614469 [TBL] [Abstract][Full Text] [Related]
11. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954 [TBL] [Abstract][Full Text] [Related]
12. Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study. Zhu H; Li R; Da Z; Bi L; Li X; Li Y; Liu C; Zhang F; Li Z; Liu X; Zhang Z; Sun L; Wang Y; Zhang W; Jiang Q; Chen J; Chen Q; Li Z; Wu L; Qi W; Xu J; Cui X; Wang X; Li L; Leng X; Wang G; Zhao D; Jiang L; He D; Liu X; Li L; Fang Y; Huang C; Wu H; Hu S; Li Q; Song H; Xiao W; Gong L; Zhang L; Li X; Li Z; Su Y Clin Rheumatol; 2018 Mar; 37(3):597-605. PubMed ID: 29116543 [TBL] [Abstract][Full Text] [Related]
13. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. Mary J; De Bandt M; Lukas C; Morel J; Combe B J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710 [TBL] [Abstract][Full Text] [Related]
14. Golimumab for rheumatoid arthritis: a systematic review. Singh JA; Noorbaloochi S; Singh G J Rheumatol; 2010 Jun; 37(6):1096-104. PubMed ID: 20436075 [TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. Singh JA; Beg S; Lopez-Olivo MA J Rheumatol; 2011 Jan; 38(1):10-20. PubMed ID: 20952462 [TBL] [Abstract][Full Text] [Related]
16. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered? Fautrel B; Den Broeder AA Best Pract Res Clin Rheumatol; 2015; 29(4-5):550-65. PubMed ID: 26697766 [TBL] [Abstract][Full Text] [Related]
17. Dose down-titration of biological disease-modifying antirheumatic drugs in daily clinical practice: Shared decision-making and patient treatment preferences in Japanese patients with rheumatoid arthritis. Komiya T; Takase-Minegishi K; Sakurai N; Nagai H; Hamada N; Soejima Y; Sugiyama Y; Tsuchida N; Kunishita Y; Kishimoto D; Kobayashi K; Kamiyama R; Yoshimi R; Kirino Y; Ohno S; Nakajima H Int J Rheum Dis; 2019 Nov; 22(11):2009-2016. PubMed ID: 31515933 [TBL] [Abstract][Full Text] [Related]
18. Treat-to-target approach in daily clinical practice in Pakistani patients with early Rheumatoid Arthritis. Farman S; Ahmad NM; Saeed MA; Asad K; Shabbir G J Coll Physicians Surg Pak; 2015 Feb; 25(2):129-33. PubMed ID: 25703758 [TBL] [Abstract][Full Text] [Related]
19. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382 [TBL] [Abstract][Full Text] [Related]
20. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]